Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

25 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence.
Kruis W, Kardalinos V, Eisenbach T, Lukas M, Vich T, Bunganic I, Pokrotnieks J, Derova J, Kondrackiene J, Safadi R, Tuculanu D, Tulassay Z, Banai J, Curtin A, Dorofeyev AE, Zakko SF, Ferreira N, Björck S, Diez Alonso MM, Mäkelä J, Talley NJ, Dilger K, Greinwald R, Mohrbacher R, Spiller R. Kruis W, et al. Among authors: dorofeyev ae. Aliment Pharmacol Ther. 2017 Aug;46(3):282-291. doi: 10.1111/apt.14152. Epub 2017 May 23. Aliment Pharmacol Ther. 2017. PMID: 28543263 Free PMC article. Clinical Trial.
Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.
Dignass A, Stoynov S, Dorofeyev AE, Grigorieva GA, Tomsová E, Altorjay I, Tuculanu D, Bunganič I, Pokrotnieks J, Kupčinskas L, Dilger K, Greinwald R, Mueller R; International Budenofalk Study Group. Dignass A, et al. Among authors: dorofeyev ae. J Crohns Colitis. 2014 Sep;8(9):970-80. doi: 10.1016/j.crohns.2014.01.021. Epub 2014 Feb 15. J Crohns Colitis. 2014. PMID: 24534142 Clinical Trial.
Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial.
Dignass A, Schnabel R, Romatowski J, Pavlenko V, Dorofeyev A, Derova J, Jonaitis L, Dilger K, Nacak T, Greinwald R; International SAT-25 Study Group. Dignass A, et al. Among authors: dorofeyev a. United European Gastroenterol J. 2018 Feb;6(1):138-147. doi: 10.1177/2050640617703842. Epub 2017 Mar 30. United European Gastroenterol J. 2018. PMID: 29435324 Free PMC article.
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis.
Andus T, Kocjan A, Müser M, Baranovsky A, Mikhailova TL, Zvyagintseva TD, Dorofeyev AE, Lozynskyy YS, Cascorbi I, Stolte M, Vieth M, Dilger K, Mohrbacher R, Greinwald R; International Salofalk Suppository OD Study Group. Andus T, et al. Among authors: dorofeyev ae. Inflamm Bowel Dis. 2010 Nov;16(11):1947-56. doi: 10.1002/ibd.21258. Inflamm Bowel Dis. 2010. PMID: 20310020 Clinical Trial.
Mucosal barrier in ulcerative colitis and Crohn's disease.
Dorofeyev AE, Vasilenko IV, Rassokhina OA, Kondratiuk RB. Dorofeyev AE, et al. Gastroenterol Res Pract. 2013;2013:431231. doi: 10.1155/2013/431231. Epub 2013 May 7. Gastroenterol Res Pract. 2013. PMID: 23737764 Free PMC article.
25 results